These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 22415035)
1. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib. Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035 [TBL] [Abstract][Full Text] [Related]
2. C-kit, GIST, and imatinib. Siehl J; Thiel E Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107 [TBL] [Abstract][Full Text] [Related]
9. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751 [TBL] [Abstract][Full Text] [Related]
11. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826 [TBL] [Abstract][Full Text] [Related]
12. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? Pantaleo MA; Di Battista M; Catena F; Astorino M; Saponara M; Di Scioscio V; Santini D; Piazzi G; Castellucci P; Brandi G; Biasco G J Cancer Res Clin Oncol; 2008 May; 134(5):625-30. PubMed ID: 18202855 [TBL] [Abstract][Full Text] [Related]
13. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
14. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation? von Mehren M; Watson JC Oncology (Williston Park); 2009 Jan; 23(1):65-6. PubMed ID: 19283923 [No Abstract] [Full Text] [Related]
15. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib]. Nishida T; Omori T; Ueshima S Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432 [TBL] [Abstract][Full Text] [Related]
16. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778 [TBL] [Abstract][Full Text] [Related]
17. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671 [TBL] [Abstract][Full Text] [Related]
18. Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report. Dizdar O; Yalcin S Hepatogastroenterology; 2011; 58(107-108):859-60. PubMed ID: 21830404 [TBL] [Abstract][Full Text] [Related]
19. Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy. Annaberdyev S; Gibbons J; Hardacre JM World J Surg Oncol; 2009 Mar; 7():30. PubMed ID: 19291285 [TBL] [Abstract][Full Text] [Related]
20. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. Hong JL; Li J; Li J; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]